Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia. more
Time Frame | CLSD | Sector | S&P500 |
---|---|---|---|
1-Week Return | 8.91% | 0.69% | 1.43% |
1-Month Return | -11.21% | -5.44% | 0.41% |
3-Month Return | -18.1% | -9.19% | 5.22% |
6-Month Return | -25.78% | -4.74% | 9.72% |
1-Year Return | -19.49% | 2.25% | 26.24% |
3-Year Return | -66.07% | -1.29% | 25.98% |
5-Year Return | -69.75% | 34.98% | 86.34% |
10-Year Return | -86.9% | 100.3% | 188.79% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 2.17M | 7.89M | 29.57M | 1.33M | 8.23M | [{"date":"2019-12-31","value":7.35,"profit":true},{"date":"2020-12-31","value":26.69,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":4.49,"profit":true},{"date":"2023-12-31","value":27.81,"profit":true}] |
Cost of Revenue | - | - | 178.00K | 204.00K | 355.00K | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":50.14,"profit":true},{"date":"2022-12-31","value":57.46,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 2.17M | 7.89M | 29.40M | 1.12M | 7.87M | [{"date":"2019-12-31","value":7.39,"profit":true},{"date":"2020-12-31","value":26.85,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":3.82,"profit":true},{"date":"2023-12-31","value":26.77,"profit":true}] |
Gross Margin | 100.00% | 100.00% | 99.40% | 84.63% | 95.68% | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":99.4,"profit":true},{"date":"2022-12-31","value":84.63,"profit":true},{"date":"2023-12-31","value":95.68,"profit":true}] |
Operating Expenses | 32.48M | 25.83M | 30.20M | 31.40M | 32.72M | [{"date":"2019-12-31","value":99.27,"profit":true},{"date":"2020-12-31","value":78.95,"profit":true},{"date":"2021-12-31","value":92.32,"profit":true},{"date":"2022-12-31","value":95.98,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (30.30M) | (17.93M) | (627.00K) | (30.28M) | (24.84M) | [{"date":"2019-12-31","value":-3030400000,"profit":false},{"date":"2020-12-31","value":-1793500000,"profit":false},{"date":"2021-12-31","value":-62700000,"profit":false},{"date":"2022-12-31","value":-3027700000,"profit":false},{"date":"2023-12-31","value":-2484400000,"profit":false}] |
Total Non-Operating Income/Expense | - | (275.00K) | 1.00M | (6.01M) | (17.00M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-27.42,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-599.1,"profit":false},{"date":"2023-12-31","value":-1695.01,"profit":false}] |
Pre-Tax Income | (30.77M) | (18.21M) | 376.00K | (32.95M) | (32.48M) | [{"date":"2019-12-31","value":-8183.51,"profit":false},{"date":"2020-12-31","value":-4843.09,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-8762.5,"profit":false},{"date":"2023-12-31","value":-8639.63,"profit":false}] |
Income Taxes | (211.00K) | (180.00K) | (58.56K) | 1.12M | (100.89K) | [{"date":"2019-12-31","value":-18.77,"profit":false},{"date":"2020-12-31","value":-16.01,"profit":false},{"date":"2021-12-31","value":-5.21,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-8.97,"profit":false}] |
Income After Taxes | - | (18.03M) | 434.56K | (34.07M) | (32.38M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-4149.04,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-7840.46,"profit":false},{"date":"2023-12-31","value":-7452.19,"profit":false}] |
Income From Continuous Operations | (30.77M) | (18.21M) | 376.00K | (29.61M) | (32.48M) | [{"date":"2019-12-31","value":-8183.51,"profit":false},{"date":"2020-12-31","value":-4843.09,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-7874.47,"profit":false},{"date":"2023-12-31","value":-8639.63,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (30.56M) | (18.03M) | 376.00K | (34.07M) | (32.48M) | [{"date":"2019-12-31","value":-8127.39,"profit":false},{"date":"2020-12-31","value":-4795.21,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-9061.53,"profit":false},{"date":"2023-12-31","value":-8639.63,"profit":false}] |
EPS (Diluted) | (0.91) | (0.39) | (0.01) | (0.55) | (0.53) | [{"date":"2019-12-31","value":-91,"profit":false},{"date":"2020-12-31","value":-39,"profit":false},{"date":"2021-12-31","value":-1,"profit":false},{"date":"2022-12-31","value":-55,"profit":false},{"date":"2023-12-31","value":-53,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
CLSD | |
---|---|
Cash Ratio | 4.22 |
Current Ratio | 4.49 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
CLSD | |
---|---|
ROA (LTM) | -44.05% |
ROE (LTM) | -1310.02% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
CLSD | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 2.19 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -1.19 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
CLSD | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 9.36 |
P/B | 3.93 |
Price/FCF | NM |
EV/R | 6.19 |
EV/Ebitda | NM |
PEG | NM |
Clearside Biomedical Inc (CLSD) share price today is $0.95
Yes, Indians can buy shares of Clearside Biomedical Inc (CLSD) on Vested. To buy Clearside Biomedical Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CLSD stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Clearside Biomedical Inc (CLSD) via the Vested app. You can start investing in Clearside Biomedical Inc (CLSD) with a minimum investment of $1.
You can invest in shares of Clearside Biomedical Inc (CLSD) via Vested in three simple steps:
The 52-week high price of Clearside Biomedical Inc (CLSD) is $2.12. The 52-week low price of Clearside Biomedical Inc (CLSD) is $0.8.
The price-to-earnings (P/E) ratio of Clearside Biomedical Inc (CLSD) is
The price-to-book (P/B) ratio of Clearside Biomedical Inc (CLSD) is 3.93
The dividend yield of Clearside Biomedical Inc (CLSD) is 0.00%
The market capitalization of Clearside Biomedical Inc (CLSD) is $70.46M
The stock symbol (or ticker) of Clearside Biomedical Inc is CLSD